SCI时时刷

search
+
Tarlatamab: First Approval
Tarlatamab: First Approval
Tarlatamab (tarlatamab-dlle: IMDELLTRA™) is a first-in-class, half-life extended bispecific delta-like ligand 3 (DLL...
Paracetamol Combination Therapy for Back Pain and Osteoarthritis: A Systematic Review and Meta-Analyses
Paracetamol Combination Therapy for Back Pain and Osteoarthritis: A Systematic Review and Meta-Analyses
Although paracetamol (acetaminophen) combined with other analgesics can reduce pain intensity in some pain conditions, its...
New and Evolving Treatments for Neurologic Dysphagia
New and Evolving Treatments for Neurologic Dysphagia
Despite swallowing being a frequently performed daily function, it is highly complex. For a safe swallow to occur, muscles...
Prevention of Rheumatoid Arthritis in At-Risk Individuals: Current Status and Future Prospects
Prevention of Rheumatoid Arthritis in At-Risk Individuals: Current Status and Future Prospects
Early intervention has been the cornerstone of improving outcomes in patients with rheumatoid arthritis. Over the past dec...
Nogapendekin alfa Inbakicept: First Approval
Nogapendekin alfa Inbakicept: First Approval
Nogapendekin alfa inbakicept (ANKTIVA®; nogapendekin alfa inbakicept-pmln) is a recombinant interleukin-15 (IL-15) su...
Zolbetuximab: First Approval
Zolbetuximab: First Approval
Zolbetuximab (VYLOY™), a recombinant, chimeric, anti-claudin 18.2 (CLDN18.2) monoclonal antibody (mAb), is being dev...
Givinostat: First Approval
Givinostat: First Approval
Givinostat (DUVYZAT™), an orally available histone deacetylase inhibitor, is being developed by Italfarmaco for the ...
Tovorafenib: First Approval
Tovorafenib: First Approval
Tovorafenib (OJEMDA™) is a once-weekly oral, selective, brain-penetrant, type II RAF kinase inhibitor being develope...
Pharmacotherapy as an Augmentation to Bariatric Surgery for Obesity
Pharmacotherapy as an Augmentation to Bariatric Surgery for Obesity
A global obesity pandemic is one of the most significant health threats worldwide owing to its close association with nume...
RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future
RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future
While activating RET fusions are identified in various cancers, lung cancer represents the most common RET fusion-positive...
Mavorixafor: First Approval
Mavorixafor: First Approval
Mavorixafor (XOLREMDI™) is an oral, selective C-X-C chemokine receptor 4 (CXCR4) antagonist developed by X4 Pharmace...
Zastaprazan: First Approval
Zastaprazan: First Approval
Zastaprazan (JAQBO®) is a next-generation potassium-competitive acid blocker being developed by Onconic Therapeutics,...
Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer’s Disease
Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer’s Disease
ALZ-801/valiltramiprosate is a small-molecule oral inhibitor of beta amyloid (Aβ) aggregation and oligomer formation ...
Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using Quantitative Systems Pharmacology Model
Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using Quantitative Systems Pharmacology Model
ALZ-801/valiltramiprosate is an oral, small-molecule inhibitor of beta-amyloid (Aβ) aggregation and oligomer formatio...
Botulinum Toxin-A for the Treatment of Myogenous Temporomandibular Disorders: An Umbrella Review of Systematic Reviews
Botulinum Toxin-A for the Treatment of Myogenous Temporomandibular Disorders: An Umbrella Review of Systematic Reviews
Temporomandibular disorders (TMDs) encompass several conditions that cause pain and impair function of the masticatory mus...
Sotatercept: First Approval
Sotatercept: First Approval
Sotatercept (sotatercept-csrk; WINREVAIRTM) is an activin signalling inhibitor that is being developed by Merck and Co., I...
Drugs Targeting Cough Receptors: New Therapeutic Options in Refractory or Unexplained Chronic Cough
Drugs Targeting Cough Receptors: New Therapeutic Options in Refractory or Unexplained Chronic Cough
Refractory chronic cough is a disabling disease with very limited therapeutic options. A better understanding of cough pat...
Anti-IL-5 Pathway Agents in Eosinophilic-Associated Disorders Across the Lifespan
Anti-IL-5 Pathway Agents in Eosinophilic-Associated Disorders Across the Lifespan
Monoclonal antibodies targeting interleukin (IL)-5 pathways have revolutionized the treatment expectations for eosinophili...
Aprocitentan: First Approval
Aprocitentan: First Approval
Aprocitentan (TRYVIO™) is a once-daily oral dual endothelin A (ETA) and B (ETB) receptor antagonist developed by Ido...
Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned
Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned
The development of new medicines for systemic lupus erythematosus (SLE) has not addressed unmet clinical need, with only t...
Sex-Based Outcomes of Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention: A Pairwise and Network Meta-Analysis
Sex-Based Outcomes of Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention: A Pairwise and Network Meta-Analysis
Although dual antiplatelet therapy (DAPT) improves the outcomes of patients undergoing percutaneous coronary intervention ...
Postpartum Depression: A Clinical Review of Impact and Current Treatment Solutions
Postpartum Depression: A Clinical Review of Impact and Current Treatment Solutions
Depression during the first year postpartum (postpartum depression) impacts millions of women and their families worldwide...
Drugs in Development to Treat IgA Nephropathy
Drugs in Development to Treat IgA Nephropathy
IgA nephropathy is a common glomerulonephritis consequent to the autoimmune response to aberrant glycosylated immunoglobul...
Ensitrelvir Fumaric Acid: First Approval
Ensitrelvir Fumaric Acid: First Approval
Ensitrelvir fumaric acid (Xocova®) is an oral SARS-CoV-2 main protease inhibitor developed by Shionogi for the treatm...
Tegileridine: First Approval
Tegileridine: First Approval
Tegileridine (艾苏特) is a small molecule μ-opioid receptor biased agonist developed by Jiangsu Hen...
Resmetirom: First Approval
Resmetirom: First Approval
Resmetirom (Rezdiffra™) is an oral thyroid hormone receptor-β (THR-β) agonist being developed by Madrigal ...
Cefepime/Enmetazobactam: First Approval
Cefepime/Enmetazobactam: First Approval
Cefepime/enmetazobactam (EXBLIFEP®), an intravenous (IV) antibacterial fixed-dose combination of a 4th generation cep...
Crovalimab: First Approval
Crovalimab: First Approval
Crovalimab (派圣凯®; PiaSky) is a humanized, anti-complement component C5 (anti-C5) recycling monoc...
Bimekizumab: A Review in Psoriatic Arthritis
Bimekizumab: A Review in Psoriatic Arthritis
Although several biological disease-modifying antirheumatic drugs (bDMARDs), including interleukin (IL)-17A inhibitors, ar...
Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines
Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines
The COVID-19 pandemic has resulted in over 772 million confirmed cases, including nearly 7 million deaths, according to th...
阅读更多
format_indent_increase